Skip to main content
OpenTrials
Completed

NCT Number: NCT00638430

The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test

The purpose of this study is to examine the effect of the myopic optical defocus on the Humphrey Matrix 30-2 test.

Completed

Looking for future studies?

Notify Me

Key information

Age range

27 year–61 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, 130-710, South Korea

About this study

The Humphery Matrix (Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA), which is a recently developed version of FDT perimetry, showed more improved technology to detect early glaucomatous damage. The user's guide for the Humphrey Matrix (Humphrey® matrix visual field instrument user's guide. Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA; 2003) suggests that myopic refractive errors more than -3.0 D need to be corrected before the 30-2 test. However, the proper correction of the optical defocus is not always easy because of a lack of trial frame.

The purpose of the present study is twofold. At first, the influence of the low-grade myopia on the Humphery Matrix 30-2 test will be evaluated and compared to the effect of moderate-grade myopia. Secondly, the influence of myopic optical defocus and the glaucomatous visual field damage on the pattern deviation plot change according to the severity of glaucomatous visual field damage will be estimated.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • intra-ocular pressure 23 or higher
  • suspicious glaucomatous optic disc change
  • suspicious defect of retinal nerve fiber layer
  • or eyes with various degrees of glaucoma

Exclusion criteria

  • a high myopic eye (SE more than -6.0 D)
  • moderate to severe cataract
  • evidence of diabetic or hypertensive retinopathy
  • macular disease
  • intra-ocular inflammation
  • history of intraocular surgery and any other ocular lesion that could have an influence on the perimetry result

Treatment and study plan

Primary outcomes

  1. mean defect

    Time frame: 15 minutes

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Important dates

Study start
2007
Primary completion
2007
Study completion
2008
First posted
Mar 19, 2008
Registry last updated
Mar 19, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.